MET and breast carcinoma: By revealing TGFβ1 as a regulator of HGF/MET‐induced cell migration, our findings suggest TGFβ1 with its downstream mediators C‐ets‐1 and miR‐128‐3p as potential targets for therapy of basal‐like breast cancer.